NO20061003L - Pyridazinlpiperainer og anvendelse derav som histamin-H3-reseptorligander - Google Patents

Pyridazinlpiperainer og anvendelse derav som histamin-H3-reseptorligander

Info

Publication number
NO20061003L
NO20061003L NO20061003A NO20061003A NO20061003L NO 20061003 L NO20061003 L NO 20061003L NO 20061003 A NO20061003 A NO 20061003A NO 20061003 A NO20061003 A NO 20061003A NO 20061003 L NO20061003 L NO 20061003L
Authority
NO
Norway
Prior art keywords
histamine
compounds
receptor
piperaines
pyridazine
Prior art date
Application number
NO20061003A
Other languages
English (en)
Norwegian (no)
Inventor
Rolf Hohlweg
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34105630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061003(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20061003L publication Critical patent/NO20061003L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20061003A 2003-07-29 2006-02-28 Pyridazinlpiperainer og anvendelse derav som histamin-H3-reseptorligander NO20061003L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301107 2003-07-29
US49269303P 2003-08-05 2003-08-05
PCT/DK2004/000483 WO2005009976A1 (fr) 2003-07-29 2004-07-06 Pyridazinyl-piperazines et leur utilisation en tant que ligands du recepteur histaminique h3

Publications (1)

Publication Number Publication Date
NO20061003L true NO20061003L (no) 2006-04-26

Family

ID=34105630

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061003A NO20061003L (no) 2003-07-29 2006-02-28 Pyridazinlpiperainer og anvendelse derav som histamin-H3-reseptorligander

Country Status (19)

Country Link
US (1) US7294626B2 (fr)
EP (1) EP1651615B1 (fr)
JP (1) JP4680903B2 (fr)
KR (1) KR20060054392A (fr)
CN (1) CN100584831C (fr)
AT (1) ATE461178T1 (fr)
AU (1) AU2004259263B2 (fr)
BR (1) BRPI0413048A (fr)
CA (1) CA2532236C (fr)
DE (1) DE602004026068D1 (fr)
DK (1) DK1651615T3 (fr)
ES (1) ES2342605T3 (fr)
IL (1) IL173161A0 (fr)
MX (1) MXPA06001053A (fr)
NO (1) NO20061003L (fr)
PL (1) PL1651615T3 (fr)
PT (1) PT1651615E (fr)
RU (1) RU2006101452A (fr)
WO (1) WO2005009976A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1430033A4 (fr) 2001-08-31 2004-12-15 Univ Northwestern Composition anti-inflammatoire et inhibitrice de la proteine kinase et methode d'utilisation
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
JP2007531753A (ja) 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非イミダゾール系複素環式化合物
EP1595881A1 (fr) * 2004-05-12 2005-11-16 Pfizer Limited Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine
BRPI0515488A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
WO2006034341A2 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
EP1799668A1 (fr) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant que modulateurs de stearoyle-coa desaturase
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580787A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et utilisation de ceux-ci comme agents therapeutiques
US20080167321A1 (en) * 2004-09-20 2008-07-10 Xenon Pharmaceuticals Inc. Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
US7592343B2 (en) * 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
WO2006050359A2 (fr) 2004-11-02 2006-05-11 Northwestern University Composes pyridazine et methodes
ES2543813T3 (es) 2004-11-02 2015-08-24 Northwestern University Compuestos de piridazina para el tratamiento de enfermedades inflamatorias
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
EP2233470B1 (fr) 2005-07-04 2011-12-07 High Point Pharmaceuticals, LLC Antagonists du receptor histamine H3
GB0517184D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
US8158673B2 (en) * 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007127375A2 (fr) 2006-04-28 2007-11-08 Northwestern University Formulations contenant un composé de pyridazine
WO2007127474A2 (fr) * 2006-04-28 2007-11-08 Northwestern University Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinestérase
JP2009537596A (ja) 2006-05-23 2009-10-29 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー 6−(4−シクロプロピルピペリジン−1−イル)−2’−メチル−[3,4’]−ビピリジン及びその医薬としての使用
SG163547A1 (en) 2006-05-29 2010-08-30 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
US7777031B2 (en) 2006-05-30 2010-08-17 Janssen Pharmaceutica Nv Substituted pyridyl amide compounds as modulators of the histamine H3 receptor
EP2049472B1 (fr) 2006-06-23 2015-01-21 AbbVie Bahamas Ltd. Dérivés de cyclopropylamines comme modulateurs du recepteur h3 de l' histamine
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CN101663292A (zh) 2007-04-23 2010-03-03 詹森药业有限公司 作为快速解离的多巴胺2受体拮抗剂的4-烷氧基哒嗪衍生物
CA2682671C (fr) 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles en tant qu'antagonistes du recepteur de la dopamine a dissociation rapide
US8653262B2 (en) 2007-05-31 2014-02-18 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
CA2689909C (fr) * 2007-06-08 2016-04-05 Ascendis Pharma As Conjugues polymeres transitoires longue duree de l'exendine
EP2014656A3 (fr) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC Nouveaux antagonistes d'hétéocycliques h3
BRPI0820481A2 (pt) 2007-11-20 2015-06-16 Janssen Pharmaceutica Nv Composotos cicloalquilóxi e heterocicloalquilóxi piridina como moduladores do receptor de h3 de histamina
CN102159554B (zh) 2008-07-03 2014-09-24 詹森药业有限公司 作为5-ht6受体拮抗剂的取代的6-(1-哌嗪基)-哒嗪
LT2307374T (lt) 2008-07-31 2017-04-25 Janssen Pharmaceutica Nv Piperazin-1-il-trifluormetil-pakeistieji piridinai kaip greitai disocijuojantys dopamino 2 receptoriaus antagonistai
PL2379525T3 (pl) 2008-12-19 2016-01-29 Centrexion Therapeutics Corp Cykliczne pirymidyno-4-karboksamidy jako antagoniści receptora CCR2 do leczenia stanów zapalnych, astmy oraz COPD
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
JP5632014B2 (ja) 2009-12-17 2014-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ccr2受容体アンタゴニスト及びこれらの使用
EP2569298B1 (fr) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Nouveaux antagonistes du récepteur ccr2, son procédé de production et utilisation associée en tant que médicaments
EP2569295B1 (fr) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH Nouveaux antagonistes du récepteur ccr2, son procédé de production et utilisation associée en tant que médicaments
JP5647339B2 (ja) 2010-05-17 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr2アンタゴニスト及びこれらの使用
EP2576542B1 (fr) * 2010-05-25 2015-04-22 Boehringer Ingelheim International GmbH Dérivés d'amide cycliques d'acides pyridazine-3-carboxyliques utiles dans le traitement de maladies respiratoires, liées à des douleurs, liées au système immunitaire et cardiovasculaires
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
EP2731941B1 (fr) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Antagonistes ccr2, nouveaux et sélectifs
WO2013151982A1 (fr) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés
FR2999427B1 (fr) * 2012-12-17 2015-01-30 Metabolys Composition et kit comprenant des derives de piperazine et de la metformine, leur utilisation dans le traitement du diabete
WO2017004537A1 (fr) 2015-07-02 2017-01-05 Centrexion Therapeutics Corporation Citrate de (4-((3r,4r)-3-méthoxytétrahydro-pyran-4-ylamino)pipéridin-1-yl)(5-méthyl-6-(((2r,6s)-(p-tolyl)tétrahydro-2h-pyran-2-yl)méthylamino)pyrimidin-4-yl)méthanone

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
FR2573075B1 (fr) * 1984-09-14 1987-03-20 Innothera Lab Sa Nouvelles (pyridyl-2)-1 piperazines, leur procede de preparation et leur application en therapeutique
CN1158269C (zh) 1997-10-27 2004-07-21 阿古龙制药公司 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物
AU2935200A (en) 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
WO2001066534A2 (fr) 2000-03-09 2001-09-13 Abbott Laboratories Antagonistes du recepteur d'histamine-3 diamino cycliques et bicycliques
AU2001251083A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
US6316475B1 (en) * 2000-11-17 2001-11-13 Abbott Laboratories Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications
EP1474401A2 (fr) * 2002-02-05 2004-11-10 Novo Nordisk A/S Nouvelles aryl- et heteroarylpiperazines

Also Published As

Publication number Publication date
CN1829699A (zh) 2006-09-06
US20060173012A1 (en) 2006-08-03
JP4680903B2 (ja) 2011-05-11
WO2005009976A1 (fr) 2005-02-03
KR20060054392A (ko) 2006-05-22
IL173161A0 (en) 2006-06-11
DE602004026068D1 (de) 2010-04-29
PT1651615E (pt) 2010-04-29
AU2004259263A1 (en) 2005-02-03
ATE461178T1 (de) 2010-04-15
MXPA06001053A (es) 2006-04-11
CA2532236C (fr) 2011-08-23
DK1651615T3 (da) 2010-05-25
PL1651615T3 (pl) 2010-08-31
JP2007500135A (ja) 2007-01-11
EP1651615B1 (fr) 2010-03-17
RU2006101452A (ru) 2006-06-27
CN100584831C (zh) 2010-01-27
EP1651615A1 (fr) 2006-05-03
AU2004259263B2 (en) 2010-12-16
US7294626B2 (en) 2007-11-13
ES2342605T3 (es) 2010-07-09
BRPI0413048A (pt) 2006-10-17
CA2532236A1 (fr) 2005-02-03

Similar Documents

Publication Publication Date Title
NO20061003L (no) Pyridazinlpiperainer og anvendelse derav som histamin-H3-reseptorligander
WO2003066604A3 (fr) Nouvelles aryl- et heteroarylpiperazines
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
DK1735278T3 (da) Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
NO20055837L (no) Immunsupprimerende forbindelser og sammensetninger
DK1957484T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
EA200601897A1 (ru) Производные тетрагидронафтиридина, пригодные в качестве лигандов рецептора н3 гистамина
NO341523B1 (no) Benzoimidazol-2-ylpyrimidiner og -pyraziner som modulatorer av histamin H4-reseptoren, farmasøytisk sammensetning samt anvendelse
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
GB0222495D0 (en) Compounds
TW200611695A (en) Pyrrolopyridine derivatives
DK1758853T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
NO20043637L (no) Amider av aminoalkylsubstituerte azetidiner, pyrrolidiner, piperidiner og azepaner
TW200800946A (en) Substituted piperazines as metabotropic glutamate receptor antagonists
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
ATE442846T1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
WO2005060959A8 (fr) Derives de pyrazone et leur utilisation en tant qu'antagonistes du recepteur de l'orexine
ATE407119T1 (de) Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
SE0300457D0 (sv) Novel compounds
DE60322110D1 (de) Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten
UA83187C2 (en) Aryl- and heteroarylpiperazines
ATE483710T1 (de) Isochinolin-3-carbonsäureamide und ihre pharmazeutische verwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application